Article
JNJ, AbbVie plan to pull US accelerated approvals for some blood cancer treatments
Rating:
0.0
Views:
63
Likes:
1
Library:
1
AbbVie Inc and partner Johnson & Johnson intend to voluntarily withdraw the accelerated approvals of their Imbruvica drug in the U.S. for patients with certain types of blood cancer, the companies said on Thursday.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value